Pirotinib - XuanZhu Pharma

Drug Profile

Pirotinib - XuanZhu Pharma

Alternative Names: KBP 5209

Latest Information Update: 04 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sihuan Pharmaceutical Holdings Group; XuanZhu Pharma
  • Class
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; ERBB 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 04 Apr 2018 China FDA approves phase I, phase II and phase III trials for pirotinib in Cancer before April 2018 (Sihuan Pharmaceutical pipeline, April 2018)
  • 02 Jun 2017 Adverse events and efficacy data from a first-in-human phase I trial presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 29 Mar 2016 Phase-I clinical trials in Solid tumours in China before March 2016 (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top